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Abstract
Background: Patients in pediatric intensive care Units (PICU) are susceptible to infections with antibiotic resistant
organisms which increase the morbidity, mortality and cost of care.
To describe the clinical characteristics and mortality in patients with Multi-Drug Resistant (MDR) gram negative
organisms. We also report safety of Polymyxin B use in these patients.
Methods: Files of patients admitted in PICU of Aga Khan University Hospital, from January 2010 to December 2011,
one month to 15 years of age were reviewed. Demographic and clinical features of patients with MDR gram
negative infections, antibiotic susceptibility pattern of isolates, discharge disposition and adverse effects of
Polymyxin B were recorded.
Results: A total of 44.8/1000(36/803) admitted patients developed MDR gram negative infections, of which 47.2%
(17/36) were male, with mean age of 3.4 yrs(+/−4.16). Acinetobacter Species (25.5%) was the most frequently isolated
MDR organisms followed by Klebsiella Pneumoniae (17%). Sensitivity of isolates was 100% to Polymyxin B, followed
by Imipenem (50%), and piperacillin/tazobactem (45%). The crude mortality rate of patients with MDR gram
negative infections was 44.4% (16/36). Fourteen of 36 patients received Polymyxin B and 57.1%; (8/14) of them
were cured. Nephrotoxicity was observed in 21.4% (3/14) cases, none of the patients showed signs of neuropathy.
Conclusion: Our study highlights high rates of Carbapenem resistant gram negative isolates, leading to increasing
use of Polymyxin B as the only drug to combat against these critically ill children. Therefore, we emphasizeon
Stewardship of Antibiotics and continuous surveillance system as strategies in overall management of these
critically ill children.
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Background
The emergence of bacterial resistance is a threat particu-
larly in Intensive Care Units (ICUs) settings, where these
organisms are prevalent and their treatment becomes a
challenge [1]. Multi-Drug Resistant (MDR) Staphylococcus
Aureus particularly –—— Methicillin Resistant Staphylo-
coccus Aureus (MRSA) has been in the limelight for long
and has been controlled in high income countries to some
extent by stringent infections control measures. However,
less attention has been given to gram negative infections
until recently, when antimicrobial resistance among gram
negative organisms and their spread raised serious public
health concerns [2-4].
High rates of antibiotic resistant pathogens have been
reported globally, in particular there are reports of rising
trends from low and low middle income countries (LMIC)
[4]. The most concerning fact is the development and
spread of Klebsiella Pneumoniae Carbapenemase(KPC),
Carbapenemase Resistant Enterobacteriacea (CRE) which
leave very few antibiotic choices. Rates of resistance are
much higher in critically ill patients. Resistance to Imipenem
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for bloodstream isolates of Acinetobacter Baumannii from
ICU patients has been reported to be as high as 85% [5].
Similarly, high resistance rates for P. Auregunosa isolates
to Imipenem and quinolones have been reported [6,7].
gram negative pathogens that are resistant to polymyxin
are also being reported from many countries and are a
cause of mortality and high health care costs [8-10]. The
reasons for development of resistance are numerous and
related to antibiotic overuse and misuse in conjunction
with poor infection control practices in health care set-
tings [11]. The development of resistance to almost all
classes of antibiotics is an alarming situation leaving physi-
cians with only few treatment options [1]. Development of
new antibiotics is limited and can be realized from the fact
that only 5 new antibiotics have been developed and
approved for use in the last decade [3]. Consequently
there has been a resurgence of old antibiotics such as
polymyxin as last resort for the treatment of infections
caused by MDR gram negative pathogens [12-15].
The rising trend of highly resistant gram negative infec-
tions has also been described in our country [16-18]. 94%
and 75% of the total gram negative isolates were resistant
to one or more antibiotics at the level of 10ug/ml and
30ug/ml respectively [17]. But these studies were done in
adults and neonatal age group [16-18]. As there is lack of
data among pediatric age group especially in critically ill
children, so we aim to describe the clinical characteristics,
antibiotic sensitivity pattern and mortality in patients with
Multi-Drug Resistant (MDR) gram negative organisms, and
also report the safety of polymyxin B use among critically
ill pediatric patients.
Methods
Files of all patients admitted in the PICU of Aga Khan
University Hospital, from January 2010 to December
2011, aged one month to 15 yrs were reviewed. The
study was approved by Ethical Review Committee of
Aga Khan University Hospital for the review of patients
medical record. (2736-PED-ERC-13) As per policy of
PICU, blood and urine cultures of all cases were sent at
the time of admission to PICU. CSF cultures were sent
for all sick infants <3 months of age and in older children if
signs and symptoms of meningitis were present. Tracheal
cultures were sent by tracheal aspiration for all ventilated
patients after 48 hours of intubation or earlier if clinical
signs are suggestive of chest infection were present.
All cultures were performed in the clinical laboratory of
Aga Khan University Hospital using standard laboratory
methods and susceptibility was performed according to
CLSI guidelines [19]. For blood cultures, Bactec 9240 blood
culture instrument was used. gram staining was performed
on positive cultures in order to identify the organisms likely
to be present. After identification conventional biochemical
tests were done to identify the specific gram negative
organism. If not identified, organisms were then identified
on analytical profile index (ANI) on BioMerieux. For Urinary
tract infections (UTIs), all specimens were inoculated on
cysteine lactose Electrolyte Deficient (CLED) Agar. If identi-
fied any growth > 105 CFU/ml, was identified, gram staining
was done, followed by conventional biochemical tests to
identify the specific gram negative organisms. For respiratory
secretions (tracheal & bronchoalveolar lavage), all speci-
mens were inoculated for quantitative culture, if identi-
fied 105 – 104 CFU/ml, then gram staining was done
followed by conventional biochemical test to identify specific
gram negative organisms. For wound cultures, specimens
(swabs/tissues/pus) were inoculated for semiquantitative
cultures. If growth occured, gram staining was done,
followed by conventional biochemical tests to identify the
specific gram negative organisms. Antibiotic susceptibility
testing was done by Kirby-Bener’s disk diffusion method
and E test for all the isolated bacteria on Mueller Hinton
Agar (MHA) to determine their resistance pattern against
common antibiotics following standards of clinical labora-
tory standard institute (CLSI, formerly National Committee
for Clinical Laboratory Standards [NCCLS]) [19,20].
Multidrug resistant organisms with resistance to imepe-
nem were tested for sensitivity to polymyxin B. A colony
count of 105 in tracheal culture was considered significant
Table 1 Clinical characteristics of critically ill pediatric
patients with MDR-Gram negative infections
Characteristics n = 36 n (%)
Height in cms (Mean+/− SD) 79.55(+/−31.2)
Weight in kg (Mean+/− SD) 11.7(+/−11.4)
Ages in yrs. (Mean +/− SD) 3.4(+/−4.16)
<1 year 19(52.7%)
1-5 years 7(19.4%)
>5 years 10(27.8%)
Gender
Male 17(47.2%)
System Involved
CVS 14(38.9%)
CNS 7(19.4%)
Respiratory 6(16.7%)
MOD 3(8.3%)
Hematological Malignancies 2(5.6%)
Renal 1(2.8%)
GIT 1(2.8%)
Others 2(5.6%)
Outcome
Discharged 20(55.6%)
Expired 16(44.4%)
MDR: Multi-Drug resistant, CVS: Cardiovascular system, CNS: Central nervous
system, MOD: Multi-organ dysfunction, GIT: Gastrointestinal tract.
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[21]. Culture proven sepsis was defined as one or more
positive blood culture collected during stay in the PICU.
Diagnosis of coagulase-negative staphylococcal sepsis
required at least 2 positive blood cultures [22]. For each pa-
tient, positive cultures from each site were counted as sep-
arate events. All information was recorded on a structured
proforma. The information collected included demographic
characteristics of patients, site of infection, antibiotic sensi-
tivity of the isolate and the mortality rate among the
infected patients. MDR was defined as resistance to 3 or
more antimicrobial groups against which it has been
tested [23]. Final disposition was defined as death related
to infection (death in the setting of clinical evidence of
active infection or within 5 days after the last positive
culture result), death unrelated to infection (death after an
episode of infection but due to causes independent of the
infectious process), or survival. Mortality was calculated
by dividing the number of patients who died within 5 days
of an infection with MDR-gram negative infections by the
total number of subjects with MDR-gram negative infec-
tion. Data on polymyxin B use among these patients,
(dose, prior and concomitant antibiotic use and, develop-
ment of nephrotoxicity) was also recorded. Nephrotoxicity
was assessed by the measurement of serum creatinine
levels before and after the use of polymyxin B, and an
increase of 100% serum creatinine level from the baseline
was considered as a marker for nephrotoxicity. Evaluation
of neurotoxicity was analyzed by going through the
recorded information on neurological examination before
and after the use of polymyxin B. The development of
neurological signs after the start of polymyxin in the
absence of any other precipitating cause was taken as a
marker for neurotoxicity due to polymyxin B. The mortality
rate amongst patients in whom polymyxin B was used, was
also reported.
Results
A total of 803 patients were admitted in the PICU during
the study period, of which 44.8/1000 (36/803) admitted
patients developed 47 episodes of MDR-gram negative
infections. Most (47.2%, 17/36) were male, 52.7% (19/36)
being under 1 year of age with mean age of 3.4 years
(+/− 4.16). The clinical and demographic characteristics
of patients who developed MDR gram negative infec-
tions are shown in Table 1. Majority of the organisms
were isolated from respiratory tract 59.6% (28/47)
followed by bloodstream infection (BSI) 25.5% (12/47),
with Acinetobacter Species (25.5%) being the most
frequently isolated organism followed by Klebsiella Pneu-
moniae (17%), Escherichia coli (14.9%) and Pseudomonas
Aeruginosa 12.8% as in Table 2. The mortality rate among
MDR-gram negative infective critically ill pediatric patients
was 44.5% (16/36), 75% were under 1 year of age, as com-
pared to overall mortality of 12.3%(99/803) in our unit.
Isolates of Acinetobacter Species were resistant to all anti-
biotics including carbapenems and tazobactems and were
sensitive only to polymyxin B (100%) and tobramycin
(66.6%). Other organisms also showed variable degree of
resistance to different classes of antibiotics, the frequency
of sensitivities to the various groups of antibiotics are
shown in Table 3. The characteristic of patients in whom
polymyxin was used is shown in Table 4. Nephrotoxicity
was observed in 21.4% (3/14) patients, of them all died,
none of the subjects developed clinical signs of neurotox-
icity. The mortality rate among patients in whom Poly-
myxin B was used was 42.9% (6/14).
Discussion
We report a high incidence of MDR gram negative infec-
tions. In another cohort the cumulative incidence of gram
negative blood stream infection was 5.4/1000 hospital
admissions of which 39% were MDR gram negative
isolates [24]. Another study in ours institute showed com-
parable incidence of 55/1000 of late onset Klebsiella Pneu-
moniae sepsis, of which 80% were resistant to multiple
antibiotics, but this study involved only neonates [16].
Most of our patients were infants constituting 52%, which
Table 2 Pathogens isolated with site of infections (n = 47)
Organisms n (%) Blood Respiratory Urine Wound Blood + Respiratory
n (%) n (%) n(%) n (%) n (%)
Acinetobacter Species 12(25.5%) 2 8 0 0 2
Klebsiella Pneumoniae 8(17.0%) 0 7 0 0 1
Pseudomonas Aeruginosa 6(12.8%) 2 4 0 0 0
Escherichia Coli 7(14.9%) 3 2 2 0 0
Enterobacter Species 5(10.6%) 2 3 0 0 0
Stenotrophomonas Maltophilia 4(8.5%) 0 3 0 0 1
Burkholderia Cepacia 2(4.3%) 2 0 0 0 0
Pseudomonas Species 3(6.4%) 1 1 0 1 0
Total n (%) 47(100%) 12(25.5%) 28(59.6%) 2(4.3%) 1(2.1%) 4(8.5%)
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Table 3 Antibiotic sensitivity of the multi-drug resistant gram negative isolates
Organisms Pip/Taz Imepenem Polymyxin B Gentamycin Amikacin Aztreonam Ceftriaxone Ceftazidime Ofloxacin Cefuroxime Amp/clav Tobramycin
Acinetobacter Species 0/12 0/12 12/12 0/12 0/12 0/6 0/12 0/12 0/12 0/8 0/2 6/9
(0%) (0%) (100%) (0%) (0%) (0%) (0%) (0%) (0%) (0%) (0%) (66.6%)
Klebsiella Pneumoniae 5/8 6/8 3/3 0/8 3/8 0/8 0/8 0/2 2/8 0/7 2/7
(62.5%) (75%) (100%) (0%) (37.5%) (0%) (0%) (0%) (25%) (0%) (28.6%)
Pseudomonas Aeruginosa 3/5 1/6 5/5 1/6 2/6 ¼ 0/3 2/4 1/6 0/2 – 0/1
(60%) (16.7%) (100%) (16.7%) (33.3%) (25%) (0%) (50%) (16.7%) (0%) (0%)
Escherichia Coli 5/7 7/7 – 5/7 7/7 0/7 0/7 0/1 4/7 0/6 3/7 –
(71.5%) (100%) (71.5%) (100%) (0%) (0%) (0%) (57.2%) (0%) (42.8%)
Enterobacter Species ¾ 4/4 – 1/5 1/5 0/4 0/4 0/1 ¼ 0/4 ¼ –
(75%) (100%) (20%) (20%) (0%) (0%) (0%) (25%) (0%) (25%)
Stenotrophomonas Maltophilia ½ – – 0/1 0/1 0/2 0/2 ½ ¾ – – –
(50%) (0%) (0%) (0%) (0%) (50%) (75%)
Burkholderia Cepacia – ½ – – – – – 2/2 2/2 – – –
(50%) (100%) (100%)
Pseudomonas Species ½ 2/3 3/3 1/3 1/3 0/3 0/3 0/1 1/3 0/1 – 0/1
(50%) (66.6%) (100%) (33.3%) (33.3%) (0%) (0%) (0%) (33.3%) (0%) (0%)
n (%) 18/40 21/42 23/23 8/42 14/42 1/34 0/39 5/25 14/46 0/28 6/20 6/11
(45%) (50%) (100%) (19.1%) (35.8%) (3%) (0%) (40%) (30.5%) (0%) (30%) (54.6%)
Pip/Taz = Piperacillin/Tazobactem Amp/Clav = Ampicillin + Clavulanic acid.
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is comparable to another study with >50% patient sunder
2 years of age excluding the neonates [24].
Among the MDR-gram negative rods, Acinetobacter spe-
cies followed by Klebsiella Pneumoniae, Escherichia coli,
and Pseudomonas Aeruginosa were the most frequently
isolated pathogens as reported earlier [25]. However in,
another study Klebsiella Pneumonia and Psuedomonas
were the most common MDR isolates [24]. Acinetobacter
species that are drug resistant and hence difficult to treat
are increasingly being reported [26-28]. Carbapenem
resistant Klebsiella and pseudomonas are also on the rise.
One study had shown an increasing trend of Klebsiella
Pneumoniae resistance to Amikacin, Flouroquinolones,
Piperacillin/Tazobactems, and Imipenem among neonates
[16]. Another study in adults showed 94% of resistance at
the level of 10ug/ml and 75% of resistance at the level of
30ul/ml among clinically isolated gram negative organisms
[17]. According to a recent report from Centre for Disease
Control and prevention (CDC), more than 70% of bacteria
responsible for health-care associated infections (HAIs)
are resistant to at least one of the antibiotics commonly
selected to treat them [1]. Therefore, increasing use of
broad spectrum antibiotics and lack of good steward-
ship has contributed to these MDR infections [29]. With
limited antibiotic options, Implementation of good antibiotic
stewardship program, Continuous surveillance System, and
stringent infection control seem to be the best available
option.
We report a high mortality rate of 42.9% in subjects
with MDR gram negative infections of which 75% were
less than 1 year of age as compared to the overall
mortality rate of 12.3% in our unit. Earlier studies have re-
ported an overall mortality between 10–53.6% [24,30-33].
However it is difficult to ascertain whether resistance was
the cause of death or other correlates like severity of the
underlying illness, prolonged antibiotic treatment and
comorbidities played a role. The high rates of infection
among critically ill patients are related to exposure to in-
vasive procedures, underlying illness, prolonged ICU stay,
antibiotic exposure and patient to patient spread [34].
With the exception of Tigecycline, a relatively recently
approved antibiotic active against MDR Acinetobacter
Baumannii, [35] no new antibiotic against the MDR-
gram negative bacteria is even in the drug development
pipeline [36]. polymyxin B and colistin (Polymyxin E)
are the two polymyxins used clinically; but the know-
ledge on pharmacokinetics and pharmacodynamics is
extremely limited, [37] and most was obtained before
1980s [12,15].
There are limited reports on use of polymyxin B in
pediatric age group [30,31]. There were only few studies
investigating the use of polymyxin B for the treatment of
infections caused by MDR-gram negative pathogens,
mostly Acinetobacter and Pseudomonas [38-40]. We
report data of 14 critically ill pediatric patients, who
received intravenous polymyxin B but despite this
almost half of them expired. Previously reported mortality
rate among MDR-gram negative infective patients with
Polymyxin use was 20-54% [38-41] which is comparable
to our data. However it is tough to decide whether the
Table 4 Characteristics of pediatric critically ill patients
with MDR-Gram negative organism with Intravenous
polymyxin B use
Characteristics n = 14 n(%)
Age median (range) 7 month ( 1 month - 12 yrs)
Gender
Males 7(50%)
Underlying disease
CVS 8(57.1%)
CNS 4(28.6%
Respiratory 2(14.3%)
Site of infection
Respiratory 11(78.6%)
BSI 1(7.1%)
BSI + Respiratory 2(14.3%)
Isolated organisms in Blood (n = 3)
Acinetobacter Species 1
Pseudomonas Aeruginosa 1
Klebsiella Pneumoniae 1
Isolated organisms in respiratory
secretions (n = 15)
Acinetobacter Species 9
Pseudomonas Aeruginosa 4
Klebsiella Pneumoniae 1
Enterobacter species 1
Antibiotics used prior to Polymyxin
B
Ceftriaxone, Meropenem,
Vancomycin
Antibiotics used concomitantly with
Polymyxin B
Meropenem, Vancomycin,
Tobramycin, Ciprofloxacin
PICU stay before instillation of IV
Polymyxin B in days median (range)
7.0(1–17 days)
Duration of IV Polymyxin B
treatment in days median (range)
8.5(2–14 days)
Dosage of Polymyxin B 40,000 IU/kg/day
Nephrotoxicity 3(21.4%)
Serum creatinine before Polymyxin B
use (mg/dl) median (range)
0.41(0.1-1.2)
Serum creatinine after Polymyxin B
use (mg/dl) median (range)
0.55(0.1-1.6)
Neurotoxicity 0
Outcome
Expired 6(42.9%)
Survived 8(57.1%)
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Polymyxin B was the cause of death or other risk factors
like severity of the underlying disease and comorbidities
etc. played a role. Nephrotoxicity and neurotoxicity were
the most potential toxicities with parenteral administra-
tion of Polymyxin B [15,42]. Incidence of nephrotoxicity
ranges from 0-37% [42]. We observed a similar rate of
nephrotoxicity. It is difficult to ascertain whether this was
due to progression of the acute kidney injury due to
underlying disease or due to the use of other nephrotoxic
drug concomitantly used with Polymyxin or primarily an
adverse effect of Polymyxin B itself. Neurotoxicity due to
Polymyxin B is usually mild and resolves after discontinu-
ation of therapy [42]. Signs of Polymyxin B induced
neurotoxicity include dizziness, generalized muscle weak-
ness, facial or peripheral paresthesia, partial deafness, visual
disturbances, vertigo, confusion, hallucinations, seizures,
ataxia, and neuromuscular weakness [39]. However, we
did not find any neurotoxicity associated with the use of
intravenous Polymyxin B.
The limitations of this study are a retrospective collec-
tion of data, limited sample size limiting determination of
risk factors for mortality among MDR gram negative
patients and inability to comment on the nephrotoxicity
of polymyxin.
Conclusion
Our study highlights high rates of carbapenem resistant
gram negative isolates, leading to increasing use of poly-
myxin B as only drug to combat against these critically ill
children. Therefore, we stress on increasing stewardship of
antibiotics and continuous surveillance system as strategies
in overall management of these critically ill children.
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